Genmab — Februar 2015
-
Just as importantly, however, also overlooked is that fact that if TGR-1202 and TG-1101(an anti CD20) both prove to be best-in-class (as is likely), they will become part of a wide range of combination therapies which would dramatically outstrip their utility and profitability as single drug therapies.
-
-
enskilda i gang igen
-
Tyder på der alligevel er lidt modstand
-
At Novod går ud og opjusterer fair value, det skal altså tages seriøst!.... For vi er vel mange der sidder og tænker - ahh Novod, det var måske lige positivt nok, ovenpå han giver en fair value på 670. Men at han så ganske kort tid efter løfter fair value, betyder altså at han mener hvert et ord og han ikke bare havde en glad dag ved seneste analyse
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind